Key Takeaway: Compass Pathways has published a post-hoc analysis from its Phase 2 study of COMP360, a synthetic psilocybin treatment for PTSD. The analysis highlights the unique monitoring and support methods employed during the trial. This publication aims to improve understanding of the treatment's efficacy and the role of support in patient outcomes.
Price reaction · baseline $13.31 (2026-07-15 close) · hit pre-market · clean, no other CMPS news in the window
day 0 close
-6.6%
day 1
-7.2%
day 3
-8.5%
Market Sentiment Analysis
POSITIVE FACTORS
Publication of a post-hoc analysis enhances understanding of treatment.
Demonstrates distinct support methods in the COMP360 trial.
Focus on innovative mental health solutions for PTSD.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~27 mo
Minimal dilution risk
Lead asset
Psilocybin
Phase 3 · Major Depressive Disorder
Full Press Release Details
LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the publication of a post-hoc analysis of support methods used in an open-label Phase 2 study of investigational COMP360 synthetic psilocybin treatment in patients with post-traumatic stress disorder (PTSD). Documented speech production between participants and support providers during treatment a
Frequently Asked Questions
What is the COMP360 trial?
The COMP360 trial is a Phase 2 study investigating synthetic psilocybin treatment for PTSD.
What does the post-hoc analysis reveal?
The analysis highlights the distinct support methods used during the COMP360 trial.
Who conducted the COMP360 trial?
The trial was conducted by Compass Pathways, a biotechnology company focused on mental health.
What is the significance of the publication?
The publication aims to enhance understanding of treatment efficacy and support roles.